Ewa Mrózek

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study”.

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study

The Oncologist(2020)10.1634/theoncologist.2020-0039

N/A

0DataRank · unranked

14 citations

Daniel G. Stover, Maryam B. Lustberg, Abigail B. Shoben, Meng Zhao, Ewa Mrózek +23 more

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07551-z

N/A

0DataRank · unranked

12 citations

H. Boutrid, Mahmoud Kassem, Mahmoud Abdel‐Rasoul, Cynthia Timmers, Maryam B. Lustberg +19 more